Cargando…

Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy

The approval of different cytokines as anti-neoplastic agents has been challenged by dose-limiting toxicities. Although reducing dose levels affords improved tolerability, efficacy is precluded at these suboptimal doses. Strategies combining cytokines with oncolytic viruses have proven to elicit pot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Nikolas T., Crupi, Mathieu J. F., Taha, Zaid, Poutou, Joanna, Whelan, Jack T., Vallati, Sydney, Petryk, Julia, Marius, Ricardo, Austin, Bradley, Azad, Taha, Boulanger, Mason, Burgess, Tamara, Sanders, Ilson, Victoor, Camille, Dickinson, Bryan C., Diallo, Jean-Simon, Ilkow, Carolina S., Bell, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224353/ https://www.ncbi.nlm.nih.gov/pubmed/37242495 http://dx.doi.org/10.3390/ph16050709

Ejemplares similares

Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
por: Crupi, Mathieu J. F., et al.
Publicado: (2022)

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
por: Boulton, Stephen, et al.
Publicado: (2023)

Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization
por: Azad, Taha, et al.
Publicado: (2020)

Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies
por: Azad, Taha, et al.
Publicado: (2023)

Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus
por: Taha, Zaid, et al.
Publicado: (2023)

From rapalogs to anti-aging formula
por: Blagosklonny, Mikhail V.
Publicado: (2017)

A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion
por: Azad, Taha, et al.
Publicado: (2021)

Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
por: Boulton, Stephen, et al.
Publicado: (2022)

Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment
por: Surendran, Abera, et al.
Publicado: (2023)

Characterization of Critical Determinants of ACE2–SARS CoV-2 RBD Interaction
por: Brown, Emily E. F., et al.
Publicado: (2021)

CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX
por: Whelan, Jack T., et al.
Publicado: (2023)

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
por: Wedge, Marie-Eve, et al.
Publicado: (2022)

Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry
por: Azad, Taha, et al.
Publicado: (2021)

SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition
por: Azad, Taha, et al.
Publicado: (2021)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
por: Hamieh, Lana, et al.
Publicado: (2018)

Rapalogs Target the Endothelium to Set the Stage for Acute Lung Injury
por: Petrache, Irina, et al.
Publicado: (2021)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells
por: Valianou, Matthildi, et al.
Publicado: (2019)

Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?
por: Blagosklonny, Mikhail V.
Publicado: (2012)

Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2
por: Shi, Guoli, et al.
Publicado: (2022)

The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
por: Arulanandam, Rozanne, et al.
Publicado: (2020)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2015)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2021)

Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
por: Achard, Carole, et al.
Publicado: (2018)

Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using (64)Cu-bevacizumab ImmunoPET
por: Chang, Albert J., et al.
Publicado: (2013)

Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma
por: Watari, Kosuke, et al.
Publicado: (2016)

Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner
por: Posada, Itziar M.D., et al.
Publicado: (2017)

The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19
por: Bischof, Evelyne, et al.
Publicado: (2021)

Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference
por: Bastin, Donald, et al.
Publicado: (2018)

Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines
por: Alluqmani, Nouf, et al.
Publicado: (2022)

Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic
por: Azad, Taha, et al.
Publicado: (2021)

Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis
por: Azad, Taha, et al.
Publicado: (2020)

Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
por: Taha, Zaid, et al.
Publicado: (2022)

Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies
por: Fergusson, Dean A., et al.
Publicado: (2019)

Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development
por: Boulton, Stephen, et al.
Publicado: (2023)

Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis
por: Sasongko, Teguh Haryo, et al.
Publicado: (2015)

Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy
por: Guan, Yidi, et al.
Publicado: (2020)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Impact of pharmacy channel on adherence to oral oncolytics
por: Stokes, Michael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h8i5jhpmq3q79ac4ihbevp10ti